Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.

International journal of radiation oncology, biology, physics - 1 Mar 2025

Ma Jennifer, Shah Rachna, Bell Andrew C, McDermott Niamh, Pei Xin, Selenica Pier, Haseltine Justin, Delsite Robert, Khan Atif J, Lok Benjamin H, Ellis Matthew J, Aft Rebecca F, Setton Jeremy, Reis-Filho Jorge S, Riaz Nadeem, Powell Simon N

Abstract excerpt

PURPOSE: Homologous recombination deficient (HRD) tumors are exquisitely sensitive to platinum-based chemotherapy and when combined with radiation therapy (RT), leads to improved overall survival in multiple cancer types. Whether a subset of tumors with distinct molecular characteristics demonstrate increased benefit from cisplatin and RT (c-RT) is unclear. We hypothesized that HRD tumors, whether associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Cisplatin

Share to Homologous Recombination

Share to Rad51 Recombinase

Share to Radiation Tolerance

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38997095
DOI: 10.1016/j.ijrobp.2024.06.037
PMCID: PMC11717987

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.PMID 38997095Read ↗

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer TypesSemantic proximity Read ↗

Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.Semantic proximity Read ↗

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy durationSemantic proximity Read ↗

Pan-cancer analysis of homologous recombination deficiency and homologous recombination repair–associated gene alterations in solid tumors from a large Asian cohortSemantic proximity Read ↗

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.Semantic proximity Read ↗

Dual Targeting of DNA Damage Response Proteins Implicated in Cancer RadioresistanceSemantic proximity Read ↗

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.Semantic proximity Read ↗

Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read ↗

Homologous recombination deficiency in cell line libraries does not correlate with in vitro sensitivity to platinum agents or PARP inhibitorsSemantic proximity Read ↗

Homologous recombination repair deficiency (HRD): From biology to clinical exploitationSemantic proximity Read ↗

Synthetic Lethality in Cancer: Mechanistic and Therapeutic Insights into PARP Inhibitors, BRCA Mutations, and Homologous Recombination Deficiency (HRD)Semantic proximity Read ↗

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.